Impact of HPV Vaccine On The Prevalence Of HPV In Norway

Impact of HPV Vaccine On The Prevalence Of Human Papillomavirus In Mouth And Vagina In Norway

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02934724

Enrollment

315

Registered

2016-10-17

Start date

2016-11-30

Completion date

2017-02-28

Last updated

2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer, Cervical Intraepithelial Neoplasia, Oropharyngeal Cancer

Keywords

HPV vaccines, HPV-6, HPV-11, HPV-16, HPV-18, Gardasil

Brief summary

The overall aim of the study is to assess the effect of school-based Human Papillomavirus (HPV) vaccination by comparing type-specific HPV prevalence between vaccinated and non-vaccinated women born in 1997. Women born in 1997, residence to Norway in 2009 (the year of vaccine initiation of the 1997-cohort) are invited to participate in the study.

Detailed description

This cohort is amongst the first that was offered HPV vaccine in an organized vaccination programme globally. The women will be recruited through Facebook ads. The study will enable us to measure differences in the prevalence of HPV types in vagina and the mouth between vaccinated and non-vaccinated young women in Norway. The womens vaccination status will be validated by linkage to the Norwegian Immunisation Registry (SYSVAK) and their residence status will be validated through linkage to the Norwegian Population Registry.

Interventions

PROCEDURESelf sample from vagina

Self sample using The Rover's Evalyn Brush

PROCEDURESelf sample from the oral cavity

Self sample using COPAN FloqSwab

OTHERQuestionnaire

Questionnaire about vaccination status and sexual behaviour

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 20 Years

Healthy volunteers

Yes

Inclusion criteria

* Female * Born in 1997 * Resident of Norway in 2009

Exclusion criteria

* Male * Born before or after 1997 * Non-resident of Norway in 2009

Design outcomes

Primary

Measure	Time frame	Description
Vaginal and oral HPV-6, HPV-11, HPV-16 and HPV-18 prevalence	Within 2 months after self-collection of specimens	The differences in HPV types prevalence among vaccinees and non-vaccinees. HPV types will be assessed individually and combined.

Secondary

Measure	Time frame
Description of oral and vaginal overall genotype distribution among vaccinated and non-vaccination participants	Within 2 months after self-collection of specimens

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026